Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib vs Adalimumab in Refractory Intestinal Behçet's Syndrome
NCT06849908Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2024
- Primary completion
- Jun 2027
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of baricitinib in Behçet's disease (BD), sponsored by Peking Union Medical College Hospital. Started Nov 2024; status: recruiting.
02
Drugs
baricitinib
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on NCT06849908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06849908.